Methylprednisolone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Methylprednisolone: From Systemic Corticosteroid Therapy to Alopecia Areata
One-Sentence Summary
Methylprednisolone is a synthetic glucocorticoid used broadly as a systemic anti-inflammatory/immunosuppressive agent (no single original indication is recorded in this evidence pack). The TxGNN model predicts it may be effective for Alopecia Areata, and the search returned 18 clinical trials and 20 publications on this drug-disease pair — though on closer review only a small subset directly evaluates methylprednisolone in alopecia areata, with the rest being off-target hits (different drugs tested for systemic lupus erythematosus, an unrelated prostate cancer trial, etc.).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not available — no original indications or license records are present in this evidence pack; methylprednisolone is a broadly used systemic glucocorticoid (anti-inflammatory/immunosuppressant) |
| Predicted New Indication | Alopecia Areata |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L2 |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on the rationale captured alongside the prediction, methylprednisolone is a broad-spectrum glucocorticoid with immunosuppressive and anti-inflammatory activity, a pharmacological class whose effects are well established in autoimmune and inflammatory conditions generally.
Alopecia areata (AA) is a T-cell–mediated autoimmune attack on the hair follicle. Systemic glucocorticoids such as methylprednisolone suppress the perifollicular lymphocytic infiltrate that drives this attack, giving a direct mechanistic link between the drug’s known immunosuppressive action and the disease process.
Importantly, this is not a novel hypothesis generated purely by the model — oral and intravenous “pulse” methylprednisolone is already an established, if second-line, option in dermatology practice for severe or treatment-resistant AA (including alopecia totalis/universalis). The TxGNN prediction here largely recovers an existing clinical practice rather than proposing an untested mechanism.
Clinical Trial Evidence
The evidence-pack search returned 18 trials for this drug-disease pair, but most were graded low relevance (Grade C) because they tested a different drug (e.g., efavaleukin alfa, baricitinib, sirolimus, olaparib) for a different disease (systemic lupus erythematosus, prostate cancer) — likely knowledge-graph disease-linkage noise rather than genuine AA evidence. The trials below are the ones actually relevant to methylprednisolone (or a closely related corticosteroid regimen) in alopecia areata:
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01167946 | Phase 4 | Completed | 42 | Oral “mega pulse” methylprednisolone tested in severe, therapy-resistant alopecia areata, using higher doses and more frequent pulses than standard regimens (Grade A — direct drug/indication match) |
| NCT07101471 | N/A (Observational) | Completed | 296 | Safety/effectiveness of tofacitinib in alopecia, with some participants receiving adjuvant prednisolone (corticosteroid-adjacent evidence) |
| NCT01017510 | N/A | Unknown | 20 | Compared intralesional steroid injection delivery methods (Dermojet vs. syringe) for alopecia areata |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32270396 | 2020 | Systematic Review | Dermatology and Therapy | Cyclosporine with and without systemic corticosteroids in alopecia areata treatment |
| 37992355 | 2023 | Review | Dermatology Practical & Conceptual | Efficacy and adverse effects of corticosteroid pulse therapy in alopecia areata |
| 35986630 | 2022 | Retrospective Cohort | Dermatologic Therapy | Methylprednisolone alone vs. methylprednisolone + methotrexate in extensive alopecia areata; combination not clearly superior |
| 25566921 | 2015 | Cohort/Case Series | Indian J Dermatol Venereol Leprol | IV methylprednisolone pulse therapy evaluated in severe alopecia areata |
| 18608727 | 2008 | Cohort | J Dermatological Treatment | Combination cyclosporine + methylprednisolone in severe alopecia areata |
| 30745958 | 2019 | Cohort | Open Access Maced J Med Sci | Methotrexate + mini-pulse methylprednisolone in severe AA (Vietnamese cohort) |
| 36865845 | 2022 | Retrospective Cohort | Indian J Dermatol | Sex differences in AA response to steroid pulse therapy |
| 36681881 | 2023 | Cohort (patient-reported) | J Eur Acad Dermatol Venereol | Long-term patient-reported outcomes of methylprednisolone pulse ± methotrexate in AA |
| 9777767 | 1998 | Open Prospective Study | J Am Acad Dermatol | Pulse methylprednisolone in 45 patients with severe AA |
| 21592197 | 2011 | Clinical Study | The Journal of Dermatology | Prognostic factors for response to methylprednisolone pulse therapy in AA (70 patients) |
US Market Information
No marketing authorization records are present in this evidence pack (0 licenses), consistent with the recorded market status of “Not marketed.” Regulatory/label data for this drug entity was not available at the time of this evaluation.
Safety Considerations
Please refer to the package insert for safety information. Key warnings, contraindications, and drug-interaction data were not available in this evidence pack (DG001 — TFDA label/warnings data is flagged as a Blocking gap for safety review).
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: A Phase 4 completed trial and multiple cohort studies/reviews support pulse methylprednisolone as an existing, clinically practiced option for severe/treatment-resistant alopecia areata — this is refinement of established practice rather than an unvalidated hypothesis. However, the absence of formal drug-label safety data and MOA detail (DG001, DG002) means safety-side evaluation cannot yet be completed.
To proceed, the following is needed:
- TFDA/regulatory package insert (warnings, contraindications) — currently blocking (DG001)
- Detailed mechanism of action data from DrugBank (DG002)
- Confirmation of licensing/marketing status, since 0 licenses are on file despite established off-label clinical use
- A monitoring plan for corticosteroid-specific risks (e.g., adrenal suppression, glucose/bone effects) given repeated pulse dosing regimens described in the literature
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.